References in periodicals archive ?
AVINZA (oral morphine sulfate extended-release capsules) is the first true once-a-day treatment for chronic moderate-to-severe pain in patients who require continuous, around-the-clock opioid therapy for an extended period of time.
Those in the Avinza morning group reported increased hours of sleep (week 1), overall improved quality of sleep (weeks 1, 2, and 4), less need for pain medications (weeks 1, 3, and 4), and less trouble falling asleep because of pain (weeks 3 and 4).
Caldwell disclosed no conflict of interest regarding the products in the study nor Avinza manufacturer Ligand Pharmaceuticals Inc.
Avinza, the new brand name for Morphelan, is a morphine sulphate extended release capsule for the once-a-day treatment of chronic and moderate to severe pain in patients who require continuous therapy over a lengthy period.
Gain on sale of AVINZA Product Line before income taxes
For example, we may not receive expected royalties on Avinza from King Pharmaceuticals, Promacta and Revolade from GSK, Conbriza from Pfizer or any other partnered products or from research and development milestones, and we may not be able to timely or successfully advance any product(s) in Ligand's pipeline.
While Flector Patch and Avinza are yet to gain traction in the pain management market, Embeda represents significant potential.
In addition, there can be no assurance that Ligand will achieve its guidance for 2010 or 2011, and the intended benefits from our proposed reverse stock split and the anticipated closure of our operations at our Cranbury, New Jersey facility, that Ligand will deliver strong cash flow over the long term, that Ligand's 2010 revenues will be driven by royalty payments related to AVINZA and PROMACTA sales, that or 2011 results of any clinical study will be timely, favorable or confirmed by later studies, that products under development by Ligand or its partners will receive regulatory approval in 2010 or later, or that there will be a market for the product(s) if successfully developed and approved.